Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Trial Profile

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 02 Sep 2011 Results presented at the 41st Annual Meeting of the International Continence Society.
    • 17 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Actual patient number (74) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top